Current pharmacologic treatments for AD, including cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine, as well as the NMDA receptor antagonist memantine, are approved by the U.S. FDA. Here, BCHE is linked to Alzheimer disease.